Tweet
My experience taking my father to China for advanced lung cancer treatment
I never thought I would be posting something like this on Baldtruthtalk, but maybe someone out there is going through something similar, so I decided to share our experience.
My father is 67 years old and was diagnosed with advanced lung cancer (EGFR mutation-positive) in 2024. In our local hospital, we had essentially gone through the standard treatment pathway: targeted therapy, chemotherapy, and immunotherapy, but the effectiveness gradually declined, and the doctors were very clear that there were limited options left.
At that point, our family was in a very desperate situation.
Later, in an online patient support group, someone mentioned that some oncology centers in China were offering more personalized combination treatment strategies, including newer targeted drugs, bispecific antibodies, and access to early clinical trials. We were initially skeptical, but after about a month of researching the available information, we decided to reach out for a consultation.
We contacted a cancer center international department in Guangzhou through DengYueMed and submitted my father’s full medical records for a remote consultation.
They eventually proposed a fairly structured treatment plan:
Optimization of the existing targeted therapy
Local radiotherapy to control the main lesions
A new-generation anti-angiogenic combination therapy
Evaluation for participation in an early-phase clinical trial (which we ultimately did not enter)
To be honest, we hesitated for a while, but eventually decided to fly to China and try it for a period of time.
During the first month of treatment in China, everything moved very quickly — frequent tests and imaging, and a very flexible approach where the treatment plan was adjusted based on results and biomarkers.
During the whole process, in addition to the anti-cancer treatment itself, there was also a strong focus on supportive care, such as pain management, nutritional support, and psychological care. In our experience, these measures contributed to a certain improvement in quality of life.
After four months, follow-up imaging showed that some of the lesions had shrunk, and his symptoms (cough and chest pain) had improved.
For us, this was already a very meaningful outcome — he was able to walk normally again, eat properly, and occasionally go out for short walks.
I’m not sure what the future holds. Cancer treatment is still complex and uncertain, and we are just trying to cherish every day we have together.
My father is 67 years old and was diagnosed with advanced lung cancer (EGFR mutation-positive) in 2024. In our local hospital, we had essentially gone through the standard treatment pathway: targeted therapy, chemotherapy, and immunotherapy, but the effectiveness gradually declined, and the doctors were very clear that there were limited options left.
At that point, our family was in a very desperate situation.
Later, in an online patient support group, someone mentioned that some oncology centers in China were offering more personalized combination treatment strategies, including newer targeted drugs, bispecific antibodies, and access to early clinical trials. We were initially skeptical, but after about a month of researching the available information, we decided to reach out for a consultation.
We contacted a cancer center international department in Guangzhou through DengYueMed and submitted my father’s full medical records for a remote consultation.
They eventually proposed a fairly structured treatment plan:
Optimization of the existing targeted therapy
Local radiotherapy to control the main lesions
A new-generation anti-angiogenic combination therapy
Evaluation for participation in an early-phase clinical trial (which we ultimately did not enter)
To be honest, we hesitated for a while, but eventually decided to fly to China and try it for a period of time.
During the first month of treatment in China, everything moved very quickly — frequent tests and imaging, and a very flexible approach where the treatment plan was adjusted based on results and biomarkers.
During the whole process, in addition to the anti-cancer treatment itself, there was also a strong focus on supportive care, such as pain management, nutritional support, and psychological care. In our experience, these measures contributed to a certain improvement in quality of life.
After four months, follow-up imaging showed that some of the lesions had shrunk, and his symptoms (cough and chest pain) had improved.
For us, this was already a very meaningful outcome — he was able to walk normally again, eat properly, and occasionally go out for short walks.
I’m not sure what the future holds. Cancer treatment is still complex and uncertain, and we are just trying to cherish every day we have together.
Attached Files